Goelzer Investment Management Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 67,960 shares of the biopharmaceutical company’s stock after selling 2,537 shares during the period. Goelzer Investment Management Inc.’s holdings in Gilead Sciences were worth $4,869,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. Bedell Frazier Investment Counseling LLC raised its stake in shares of Gilead Sciences by 42.4% in the 4th quarter. Bedell Frazier Investment Counseling LLC now owns 99,125 shares of the biopharmaceutical company’s stock valued at $7,101,000 after acquiring an additional 29,536 shares during the period. Teacher Retirement System of Texas raised its stake in shares of Gilead Sciences by 47.9% in the 4th quarter. Teacher Retirement System of Texas now owns 1,301,053 shares of the biopharmaceutical company’s stock valued at $93,207,000 after acquiring an additional 421,437 shares during the period. AE Wealth Management LLC raised its stake in shares of Gilead Sciences by 413.1% in the 4th quarter. AE Wealth Management LLC now owns 16,389 shares of the biopharmaceutical company’s stock valued at $1,174,000 after acquiring an additional 13,195 shares during the period. Hyman Charles D raised its stake in shares of Gilead Sciences by 35.9% in the 4th quarter. Hyman Charles D now owns 4,164 shares of the biopharmaceutical company’s stock valued at $298,000 after acquiring an additional 1,100 shares during the period. Finally, Reynders McVeigh Capital Management LLC raised its stake in shares of Gilead Sciences by 41.0% in the 4th quarter. Reynders McVeigh Capital Management LLC now owns 68,079 shares of the biopharmaceutical company’s stock valued at $4,877,000 after acquiring an additional 19,800 shares during the period. 77.83% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director John Francis Cogan sold 5,833 shares of Gilead Sciences stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $80.09, for a total value of $467,164.97. Following the completion of the transaction, the director now directly owns 58,452 shares of the company’s stock, valued at approximately $4,681,420.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $73.87, for a total transaction of $1,108,050.00. Following the completion of the transaction, the executive vice president now directly owns 64,613 shares of the company’s stock, valued at $4,772,962.31. The disclosure for this sale can be found here. Insiders sold a total of 436,101 shares of company stock valued at $34,541,560 over the last ninety days. Company insiders own 1.30% of the company’s stock.
GILD stock opened at $76.92 on Wednesday. The firm has a market cap of $101,103.33, a price-to-earnings ratio of 22.10, a price-to-earnings-growth ratio of -1.77 and a beta of 1.24. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm’s revenue for the quarter was down 18.7% compared to the same quarter last year. During the same period last year, the business earned $2.70 EPS. sell-side analysts predict that Gilead Sciences, Inc. will post 6.21 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a $0.57 dividend. The ex-dividend date is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 2.96%. Gilead Sciences’s payout ratio is 65.52%.
A number of brokerages have recently commented on GILD. Barclays reissued an “overweight” rating and issued a $95.00 target price (up previously from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Mizuho set a $95.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Monday, February 5th. Finally, TheStreet lowered shares of Gilead Sciences from a “b-” rating to a “c” rating in a report on Tuesday, February 6th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $88.61.
TRADEMARK VIOLATION NOTICE: This report was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/03/21/goelzer-investment-management-inc-cuts-stake-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.